An adenoviral-vectored vaccine confers seroprotection against capsular group B meningococcal disease

Overview of attention for article published in Science Translational Medicine, June 2023

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (95th percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

news: 6 news outlets
twitter: 8 X users

reddit: 1 Redditor

Readers on

mendeley: 15 Mendeley

So far, Altmetric has seen 9 X posts from 8 X users, with an upper bound of 46,664 followers.

RT @SynthIge: Mass murderers @OxfordVacGroup @ajpollard1 unsatisfied with 1000s they killed with the COVID clot shot, plan more mass deaths…

Bad. przedkliniczne🇬🇧: wektorowa 💉p/ meningokokom indukowała silne i trwałe odp. bakteriobójczych przeciwciał w surowicy (SBA). Wyniki podkreślają potencjał 💉opartych na materiale genetycznym do uodparniania p/chorobie wywołanej przez meningokoki typu B…

Et une protection plus efficace contre le gonocoque...? 🤞

RT @ScienceTM: An adenoviral vaccine for group B #meningococcus—a leading cause of meningitis and septicemia—elicits strong antigen-specifi…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 5 additional X posts.